Literature DB >> 9210053

Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria.

C Daumas-Duport1, M L Tucker, H Kolles, P Cervera, F Beuvon, P Varlet, N Udo, M Koziak, J P Chodkiewicz.   

Abstract

This second part of our study of 'pure' oligodendrogliomas focuses on survival data analysis. In order to identify potentially useful prognostic factors and to assess the effectiveness of a new grading system, the 79 patients in the previously analyzed series for whom adequate follow-up could be obtained (52%) were entered in the present analysis. Statistical analysis demonstrated that contrast enhancement and endothelial hyperplasia had powerful and similar influence on survival. Median survival with and without contrast enhancement were: 3 versus 11 years, and with or without endothelial hyperplasia were: 3.5 versus 11 years. Conversely, the degree of nuclear atypia and presence or absence of mitosis or necrosis were not correlated with survival. These findings allowed us to devise a simple grading system which discriminates two malignancy grades as follows: absence of endothelial hyperplasia and of contrast enhancement = Grade A, presence of endothelial hyperplasia and/or of contrast enhancement = Grade B. Of the 79 oligodendrogliomas in this study, 59 tumors were categorized as grade A and 20 as grade B. Median survival were: 11 years in grade A and 3.5 years in grade B. Five-year and 8-year survival rates were: 89% and 60% in grade A and: 33% and 15% in grade B. Double blind grading between two independent observers was concordant in 96% of the cases. Application of this simple efficient and reproducible grading scheme should permit reliable comparison of retrospective or prospective therapeutic data emanating from various institutions.

Entities:  

Mesh:

Year:  1997        PMID: 9210053     DOI: 10.1023/a:1005759220434

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  31 in total

1.  Oligodendroglioma. A comparison of two grading systems.

Authors:  J M Kros; D Troost; C G van Eden; A J van der Werf; H B Uylings
Journal:  Cancer       Date:  1988-06-01       Impact factor: 6.860

2.  Oligodendrogliomas; a review of 200 cases.

Authors:  F EARNEST; J W KERNOHAN; W M CRAIG
Journal:  Arch Neurol Psychiatry       Date:  1950-06

3.  The role of postoperative irradiation in the treatment of oligodendroglioma.

Authors:  D E Gannett; W M Wisbeck; D L Silbergeld; M S Berger
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-10-15       Impact factor: 7.038

4.  Oligodendroglioma: an analysis of 42 cases.

Authors:  I M Wilkinson; J R Anderson; A E Holmes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-03       Impact factor: 10.154

5.  Oligodendroglioma: the Rotterdam-Dijkzigt experience.

Authors:  J M Kros; H Pieterman; C G van Eden; C J Avezaat
Journal:  Neurosurgery       Date:  1994-06       Impact factor: 4.654

6.  Oligodendroglioma. Histologic evaluation and prognosis.

Authors:  S J Mørk; T B Halvorsen; K F Lindegaard; G E Eide
Journal:  J Neuropathol Exp Neurol       Date:  1986-01       Impact factor: 3.685

7.  Oligodendrogliomas. I. A clinical study of cerebral oligodendrogliomas.

Authors:  H W Chin; J J Hazel; T H Kim; J H Webster
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

8.  Oligodendrogliomas: the Mayo Clinic experience.

Authors:  E G Shaw; B W Scheithauer; J R O'Fallon; H D Tazelaar; D H Davis
Journal:  J Neurosurg       Date:  1992-03       Impact factor: 5.115

9.  Oligodendroglioma. An analysis of the value of radiation therapy.

Authors:  D E Bullard; C E Rawlings; B Phillips; E B Cox; S C Schold; P Burger; E C Halperin
Journal:  Cancer       Date:  1987-11-01       Impact factor: 6.860

10.  Cerebral oligodendroglioma: prognostic factors and life history.

Authors:  P Celli; I Nofrone; L Palma; G Cantore; A Fortuna
Journal:  Neurosurgery       Date:  1994-12       Impact factor: 4.654

View more
  41 in total

1.  The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases.

Authors:  A Korshunov; A Golanov
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Extradural cord compression due to metastatic oligodendroglioma.

Authors:  Jeff Garner; Yehya Morcos; Mohammed Bari
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

3.  Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas.

Authors:  Johan Pallud; Jean-François Llitjos; Frédéric Dhermain; Pascale Varlet; Edouard Dezamis; Bertrand Devaux; Raphaëlle Souillard-Scémama; Nader Sanai; Maria Koziak; Philippe Page; Michel Schlienger; Catherine Daumas-Duport; Jean-François Meder; Catherine Oppenheim; François-Xavier Roux
Journal:  Neuro Oncol       Date:  2012-03-13       Impact factor: 12.300

4.  Glioma dissemination along the corticospinal tract.

Authors:  J Pallud; B Devaux; C Daumas-Duport; C Oppenheim; F X Roux
Journal:  J Neurooncol       Date:  2005-07       Impact factor: 4.130

5.  The presence of necrosis and/or microvascular proliferation does not influence survival of patients with anaplastic oligodendroglial tumours: review of 98 patients.

Authors:  Sarah F Smith; Judy M Simpson; Janice A Brewer; Lali H S Sekhon; Michael T Biggs; Raymond J Cook; Nicholas S Little
Journal:  J Neurooncol       Date:  2006-06-23       Impact factor: 4.130

Review 6.  Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm.

Authors:  Emmanuel Mandonnet; Johan Pallud; Olivier Clatz; Luc Taillandier; Ender Konukoglu; Hugues Duffau; Laurent Capelle
Journal:  Neurosurg Rev       Date:  2008-02-26       Impact factor: 3.042

Review 7.  PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI.

Authors:  S Diabira; M C Rousselet; E Gamelin; P Soulier; E Jadaud; P Menei
Journal:  J Neurooncol       Date:  2001-10       Impact factor: 4.130

8.  Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?

Authors:  Matthew L White; Yan Zhang; Patricia Kirby; Timothy C Ryken
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

9.  Prognostic significance of CT contrast enhancement within histological subgroups of intracranial glioma.

Authors:  K Lote; T Egeland; B Hager; K Skullerud; H Hirschberg
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

10.  High and low grade oligodendrogliomas (ODG): correlation of amino-acid and glucose uptakes using PET and histological classifications.

Authors:  F Giammarile; L E Cinotti; A Jouvet; J M Ramackers; G Saint Pierre; P Thiesse; E Jouanneau; J Guyotat; I Pelissou-Guyotat; A Setiey; J Honnorat; D Le Bars; D Frappaz
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.